Christopher Mutz's Insider Trades & SAST Disclosures
Christopher Mutz's most recent trade in ANI Pharmaceuticals Inc was a trade of 4,000 Common Stock done at an average price of $60.5 . Disclosure was reported to the exchange on May 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Christopher Mutz.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Sale of securities on an exchange or to another person at price $ 60.45 per share. | 14 May 2025 | 4,000 | 107,317 (0%) | 0% | 60.5 | 241,800 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 60.62 per share. | 07 Mar 2025 | 2,874 | 111,317 (0%) | 0% | 60.6 | 174,222 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 61.89 per share. | 28 Feb 2025 | 1,275 | 114,191 (0%) | 0% | 61.9 | 78,910 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 24,808 | 101,585 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 16,538 | 118,123 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.92 per share. | 12 Feb 2025 | 1,473 | 116,650 (0%) | 0% | 58.9 | 86,789 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.92 per share. | 12 Feb 2025 | 1,184 | 115,466 (0%) | 0% | 58.9 | 69,761 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Sale of securities on an exchange or to another person at price $ 57.70 per share. | 15 Nov 2024 | 6,500 | 76,777 (0%) | 0% | 57.7 | 375,050 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Sale of securities on an exchange or to another person at price $ 61.61 per share. | 21 May 2024 | 2,000 | 83,277 (0%) | 0% | 61.6 | 123,220 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 66.71 per share. | 07 Mar 2024 | 2,110 | 85,277 (0%) | 0% | 66.7 | 140,758 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Sale of securities on an exchange or to another person at price $ 66.00 per share. | 05 Mar 2024 | 5,000 | 87,387 (0%) | 0% | 66 | 330,000 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 67.67 per share. | 29 Feb 2024 | 1,275 | 92,387 (0%) | 0% | 67.7 | 86,279 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.55 per share. | 15 Feb 2024 | 1,261 | 93,662 (0%) | 0% | 57.6 | 72,571 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 18,790 | 82,397 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Mutz Christopher | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 12,526 | 94,923 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.23 per share. | 07 Mar 2023 | 1,426 | 38,136 (0%) | 0% | 44.2 | 63,072 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.23 per share. | 07 Mar 2023 | 476 | 37,660 (0%) | 0% | 44.2 | 21,053 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 17,369 | 55,029 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2023 | 11,578 | 66,607 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.04 per share. | 15 Feb 2023 | 1,292 | 39,562 (0%) | 0% | 45.0 | 58,192 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2022 | 6,476 | 40,854 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2022 | 19,428 | 34,378 (0%) | 0% | 0 | Common Stock | |
| ANI Pharmaceuticals Inc | Christopher Mutz | HEAD OF RARE DISEASE | Payment of exercise price or tax liability using portion of securities received from the company at price $ 40.25 per share. | 15 Feb 2022 | 1,184 | 14,950 (0%) | 0% | 40.3 | 47,656 | Common Stock |
| ANI Pharmaceuticals Inc | Christopher Mutz | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 33,758 | 33,758 | - | - | Stock Option (right to buy) | |
| ANI Pharmaceuticals Inc | Christopher Mutz | CHIEF COMMERCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2021 | 16,134 | 16,134 (0%) | 0% | 0 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges